— Research note —
Tesamorelin
N-terminally modified GHRH analog investigated in clinical research for HIV-associated visceral adipose tissue and metabolic endpoints.
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) in which a trans-3-hexenoyl moiety is conjugated to the N-terminal tyrosine residue of the GHRH (1-44) sequence. This N-terminal lipid modification confers resistance to cleavage by dipeptidyl peptidase-4, extending the in vivo half-life relative to native GHRH while preserving full agonist activity at the GHRH receptor. The molecule was developed by Theratechnologies (Montreal) and received regulatory approval in the United States in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, making it one of the few GHRH analogs to reach pharmaceutical approval.
In clinical research, tesamorelin has been investigated primarily in the context of HIV-associated lipohypertrophy, with phase 3 trials reporting reductions in visceral adipose tissue measured by computed tomography. Subsequent research has examined the molecule in non-HIV settings including non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatohepatitis (MASH), with reports of reductions in hepatic fat fraction measured by magnetic resonance spectroscopy.
The compound has also been studied in cognitive research applications. A phase 2 study published in the Archives of Neurology examined tesamorelin in adults with mild cognitive impairment and reported effects on memory performance and brain metabolite concentrations. These investigations reflect broader research interest in the role of growth hormone and IGF-1 axis modulation in age-related cognitive change.
Tesamorelin is supplied here for laboratory research use only and is not intended for human consumption. The compound serves as a reference molecule in academic studies of GHRH pharmacology, hepatic lipid metabolism, and the relationship between somatotropic axis activity and visceral adipose biology.
Mechanism
Tesamorelin binds the GHRH receptor with affinity comparable to native GHRH, activating Gas, elevating intracellular cAMP, and stimulating pulsatile growth hormone release from pituitary somatotrophs. The N-terminal trans-3-hexenoyl modification blocks recognition by dipeptidyl peptidase-4, the principal degradative enzyme of native GHRH, extending plasma half-life from minutes to approximately 26 to 38 minutes.
Downstream consequences of repeated GHRH receptor activation include sustained elevations of IGF-1, which mediates many of the metabolic effects observed in clinical research. Tesamorelin administration in research populations has been associated with reductions in visceral adipose tissue, decreased hepatic triglyceride content, and modest changes in lipid profiles. Mechanistic explanations include increased lipolysis in visceral adipose depots, altered hepatic substrate handling, and improved insulin sensitivity in specific tissue compartments.
Research history
Theratechnologies developed tesamorelin in the 2000s with the explicit goal of identifying a stabilized GHRH analog suitable for chronic administration in HIV-associated lipodystrophy, a then-prevalent metabolic complication of antiretroviral therapy. Phase 3 pivotal trials published in 2007 and 2010 demonstrated reductions in visceral adipose tissue and supported regulatory approval.
Subsequent research extended the molecule into non-HIV metabolic research. A landmark study published in JAMA in 2014 by Stanley and colleagues at Massachusetts General Hospital reported reductions in hepatic fat fraction in HIV-infected adults with NAFLD. A 2019 publication extended findings to non-HIV NAFLD populations with similar hepatic effects.
The Friedman group and others investigated tesamorelin in cognitive research, with a phase 2 study reporting effects on memory and brain metabolites in mild cognitive impairment. Recent research has examined the compound in heart failure with preserved ejection fraction and in additional metabolic contexts. Tesamorelin remains one of the few approved GHRH analogs and continues to serve as a reference compound in clinical and academic GHRH pharmacology.
References
- Falutz J, et al. 2007. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. PMID: 17898100
- Stanley TL, et al. 2014. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. PMID: 25313728
- Stanley TL, et al. 2019. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. PMID: 31655019
- Baker LD, et al. 2012. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol. PMID: 22782513
- Falutz J, et al. 2010. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat. J Clin Endocrinol Metab. PMID: 20660034
- Adrian S, et al. 2019. The growth hormone-releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area. AIDS. PMID: 31490212
Do you have any questions about Tesamorelin?
Pick a path. The research assistant has the full literature context loaded.
Information presented in third-person scientific context. Research use only. Not medical advice; not for human consumption.